Author:
Verweij Jaap,Longson Carole,von Lilienfeld-Toal Marie,Cahane David,Jeffry Evans Thomas R.,Chiou Victoria L.,Lacombe Denis,Gravis Gwenaelle,Goldstein Daniel A
Reference62 articles.
1. Reporting of participant race, sex, and socioeconomic status in randomized clinical trials in general medical journals, 2015 vs 2019;Alegria;JAMA Network Open,2021
2. How soon will digital endpoints become a cornerstone for future drug development?;Boehme;Drug Discovery Today,2019
3. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates;Brahmer;Journal of Clinical Oncology,2010
4. Consideration of older patients for enrollment in phase 1 clinical trials: Exploring treatment related toxicities and outcomes;Buechel;Gynecologic Oncology,2018
5. Real-world data for regulatory decision making. Challenges and possible solutions for Europe;Cave;Clinical Pharmacology and Therapeutics,2019